FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200301557> ?p ?o ?g. }

• W4200301557 abstract "Primary membranous nephropathy (PMN) is a common cause of nephrotic syndrome in adults. Without treatment, approximately 30% of patients will experience spontaneous remission and one third will have persistent proteinuria. Approximately one-third of patients progress toward end-stage kidney disease (ESKD) within 10 years. Immunosuppressive treatment aims to protect kidney function and is recommended for patients who do not show improvement of proteinuria by supportive therapy, and for patients with severe nephrotic syndrome at presentation due to the high risk of developing ESKD. The efficacy and safety of different immunosuppressive regimens are unclear. This is an update of a Cochrane review, first published in 2004 and updated in 2013.The aim was to evaluate the safety and efficacy of different immunosuppressive treatments for adult patients with PMN and nephrotic syndrome.We searched the Cochrane Kidney and Transplant Register of Studies up to 1 April 2021 with support from the Cochrane Kidney and Transplant Information Specialist using search terms relevant to this review. Studies in the Register were identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.Randomised controlled trials (RCTs) investigating effects of immunosuppression in adults with PMN and nephrotic syndrome were included.Study selection, data extraction, quality assessment, and data synthesis were performed using Cochrane-recommended methods. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous outcomes. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.Sixty-five studies (3807 patients) were included. Most studies exhibited a high risk of bias for the domains, blinding of study personnel, participants and outcome assessors, and most studies were judged unclear for randomisation sequence generation and allocation concealment. Immunosuppressive treatment versus placebo/no treatment/non-immunosuppressive treatment In moderate certainty evidence, immunosuppressive treatment probably makes little or no difference to death, probably reduces the overall risk of ESKD (16 studies, 944 participants: RR 0.59, 95% CI 0.35 to 0.99; I² = 22%), probably increases total remission (complete and partial) (6 studies, 879 participants: RR 1.44, 95% CI 1.05 to 1.97; I² = 73%) and complete remission (16 studies, 879 participants: RR 1.70, 95% CI 1.05 to 2.75; I² = 43%), and probably decreases the number with doubling of serum creatinine (SCr) (9 studies, 447 participants: RR 0.46, 95% CI 0.26 to 0.80; I² = 21%). However, immunosuppressive treatment may increase the number of patients relapsing after complete or partial remission (3 studies, 148 participants): RR 1.73, 95% CI 1.05 to 2.86; I² = 0%) and may lead to a greater number experiencing temporary or permanent discontinuation/hospitalisation due to adverse events (18 studies, 927 participants: RR 5.33, 95% CI 2.19 to 12.98; I² = 0%). Immunosuppressive treatment has uncertain effects on infection and malignancy. Oral alkylating agents with or without steroids versus placebo/no treatment/steroids Oral alkylating agents with or without steroids had uncertain effects on death but may reduce the overall risk of ESKD (9 studies, 537 participants: RR 0.42, 95% CI 0.24 to 0.74; I² = 0%; low certainty evidence). Total (9 studies, 468 participants: RR 1.37, 95% CI 1.04 to 1.82; I² = 70%) and complete remission (8 studies, 432 participants: RR 2.12, 95% CI 1.33 to 3.38; I² = 37%) may increase, but had uncertain effects on the number of patients relapsing, and decreasing the number with doubling of SCr. Alkylating agents may be associated with a higher rate of adverse events leading to discontinuation or hospitalisation (8 studies 439 participants: RR 6.82, 95% CI 2.24 to 20.71; I² = 0%). Oral alkylating agents with or without steroids had uncertain effects on infection and malignancy. Calcineurin inhibitors (CNI) with or without steroids versus placebo/no treatment/supportive therapy/steroids We are uncertain whether CNI with or without steroids increased or decreased the risk of death or ESKD, increased or decreased total or complete remission, or reduced relapse after complete or partial remission (low to very low certainty evidence). CNI also had uncertain effects on decreasing the number with a doubling of SCr, temporary or permanent discontinuation or hospitalisation due to adverse events, infection, or malignancy. Calcineurin inhibitors (CNI) with or without steroids versus alkylating agents with or without steroids We are uncertain whether CNI with or without steroids increases or decreases the risk of death or ESKD. CNI with or without steroids may make little or no difference to total remission (10 studies, 538 participants: RR 1.01, 95% CI 0.89 to 1.15; I² = 53%; moderate certainty evidence) or complete remission (10 studies, 538 participants: RR 1.15, 95% CI 0.84 to 1.56; I² = 56%; low certainty evidence). CNI with or without steroids may increase relapse after complete or partial remission. CNI with or without steroids had uncertain effects on SCr increase, adverse events, infection, and malignancy. Other immunosuppressive treatments Other interventions included azathioprine, mizoribine, adrenocorticotropic hormone, traditional Chinese medicines, and monoclonal antibodies such as rituximab. There were insufficient data to draw conclusions on these treatments.This updated review strengthened the evidence that immunosuppressive therapy is probably superior to non-immunosuppressive therapy in inducing remission and reducing the number of patients that progress to ESKD. However, these benefits need to be balanced against the side effects of immunosuppressive drugs. The number of included studies with high-quality design was relatively small and most studies did not have adequate follow-up. Clinicians should inform their patients of the lack of high-quality evidence. An alkylating agent (cyclophosphamide or chlorambucil) combined with a corticosteroid regimen had short- and long-term benefits, but this was associated with a higher rate of adverse events. CNI (tacrolimus and cyclosporin) showed equivalency with alkylating agents however, the certainty of this evidence remains low. Novel immunosuppressive treatments with the biologic rituximab or use of adrenocorticotropic hormone require further investigation and validation in large and high-quality RCTs." @default.
• W4200301557 created "2021-12-31" @default.
• W4200301557 creator A5000766210 @default.
• W4200301557 creator A5019056919 @default.
• W4200301557 creator A5021328880 @default.
• W4200301557 creator A5026026298 @default.
• W4200301557 creator A5044527438 @default.
• W4200301557 creator A5051609819 @default.
• W4200301557 creator A5061190885 @default.
• W4200301557 date "2021-11-15" @default.
• W4200301557 modified "2023-10-16" @default.
• W4200301557 title "Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome" @default.
• W4200301557 cites W111303890 @default.
• W4200301557 cites W1190767899 @default.
• W4200301557 cites W1535106252 @default.
• W4200301557 cites W1537972189 @default.
• W4200301557 cites W1566635326 @default.
• W4200301557 cites W1583849384 @default.
• W4200301557 cites W1751540524 @default.
• W4200301557 cites W1853153242 @default.
• W4200301557 cites W1905774568 @default.
• W4200301557 cites W1963948820 @default.
• W4200301557 cites W1965172991 @default.
• W4200301557 cites W1966123366 @default.
• W4200301557 cites W1970322783 @default.
• W4200301557 cites W1981507875 @default.
• W4200301557 cites W1982367409 @default.
• W4200301557 cites W1986253422 @default.
• W4200301557 cites W1989010792 @default.
• W4200301557 cites W1995726392 @default.
• W4200301557 cites W1998442004 @default.
• W4200301557 cites W1999677111 @default.
• W4200301557 cites W2000001694 @default.
• W4200301557 cites W2005989846 @default.
• W4200301557 cites W2007237295 @default.
• W4200301557 cites W2007501720 @default.
• W4200301557 cites W2013232123 @default.
• W4200301557 cites W2016537170 @default.
• W4200301557 cites W2019518678 @default.
• W4200301557 cites W2020987938 @default.
• W4200301557 cites W2022410602 @default.
• W4200301557 cites W2022663495 @default.
• W4200301557 cites W2025162579 @default.
• W4200301557 cites W2027077465 @default.
• W4200301557 cites W2029198423 @default.
• W4200301557 cites W2035327670 @default.
• W4200301557 cites W2036840908 @default.
• W4200301557 cites W2037365119 @default.
• W4200301557 cites W2039760414 @default.
• W4200301557 cites W2040060591 @default.
• W4200301557 cites W2040104469 @default.
• W4200301557 cites W2044080899 @default.
• W4200301557 cites W2049080168 @default.
• W4200301557 cites W2049648051 @default.
• W4200301557 cites W2050449333 @default.
• W4200301557 cites W2051090119 @default.
• W4200301557 cites W2056197094 @default.
• W4200301557 cites W2071057112 @default.
• W4200301557 cites W2073033781 @default.
• W4200301557 cites W2073342404 @default.
• W4200301557 cites W2074443840 @default.
• W4200301557 cites W2083760961 @default.
• W4200301557 cites W2090021700 @default.
• W4200301557 cites W2091693558 @default.
• W4200301557 cites W2095787590 @default.
• W4200301557 cites W2104602296 @default.
• W4200301557 cites W2104675861 @default.
• W4200301557 cites W2111285312 @default.
• W4200301557 cites W2111892488 @default.
• W4200301557 cites W2115472834 @default.
• W4200301557 cites W2116986363 @default.
• W4200301557 cites W2118253697 @default.
• W4200301557 cites W2122493005 @default.
• W4200301557 cites W2123048854 @default.
• W4200301557 cites W2125435699 @default.
• W4200301557 cites W2135619376 @default.
• W4200301557 cites W2135952429 @default.
• W4200301557 cites W2137807773 @default.
• W4200301557 cites W2140565611 @default.
• W4200301557 cites W2141219630 @default.
• W4200301557 cites W2144504916 @default.
• W4200301557 cites W2146020479 @default.
• W4200301557 cites W2146086822 @default.
• W4200301557 cites W2150069482 @default.
• W4200301557 cites W2150460695 @default.
• W4200301557 cites W2157296439 @default.
• W4200301557 cites W2158860655 @default.
• W4200301557 cites W2160726185 @default.
• W4200301557 cites W2165010366 @default.
• W4200301557 cites W2166721512 @default.
• W4200301557 cites W2166822765 @default.
• W4200301557 cites W2211752697 @default.
• W4200301557 cites W2226729375 @default.
• W4200301557 cites W2260911688 @default.
• W4200301557 cites W2267406432 @default.
• W4200301557 cites W2275781080 @default.
• W4200301557 cites W2301544544 @default.
• W4200301557 cites W2322148317 @default.
• W4200301557 cites W2326202408 @default.
• W4200301557 cites W2335807041 @default.

• next